000			01788 a2200445 4500
005			20250517193615.0
264		0	_c20180423
008			201804s 0 0 eng d
022			_a1524-4733
024	7		_a10.1016/j.jval.2017.05.025 _2doi
040			_aNLM _beng _cNLM
100	1		_aPapp, Kim A
245	0	0	_aComparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials. _h[electronic resource]
260			_bValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research _c01 2018
300			_a1-8 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdalimumab _xtherapeutic use
650	0	4	_aAdult
650	0	4	_aAnti-Inflammatory Agents _xtherapeutic use
650	0	4	_aAnti-Inflammatory Agents, Non-Steroidal _xtherapeutic use
650	0	4	_aClinical Trials, Phase III as Topic
650	0	4	_aEtanercept _xtherapeutic use
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aPropensity Score
650	0	4	_aPsoriasis _xdrug therapy
650	0	4	_aQuality of Life
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aSeverity of Illness Index
650	0	4	_aTreatment Outcome
700	1		_aYang, Min
700	1		_aSundaram, Murali
700	1		_aJarvis, John
700	1		_aBetts, Keith A
700	1		_aBao, Yanjun
700	1		_aSignorovitch, James E
773	0		_tValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research _gvol. 21 _gno. 1 _gp. 1-8
856	4	0	_uhttps://doi.org/10.1016/j.jval.2017.05.025 _zAvailable from publisher's website
999			_c27951704 _d27951704